New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to Humira

March 6, 2017 6:33 AM

Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab (GP2017). The Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint demonstrating GP2017 has equivalent efficacy to the reference medicine, Humira.

Results were presented at the American Academy of Dermatology (AAD) in Orlando, Florida.

The primary endpoint of the study was the proportion of patients who achieved a 75% improvement at Week 16, as measured by the Psoriasis Area and Severity Index (PASI). Data from the study confirmed equivalent efficacy by demonstrating PASI 75 response rates of 67% for proposed biosimilar adalimumab and 65% for the reference medicine in patients with moderate to severe, chronic plaque psoriasis.

“Currently, it is estimated that as few as five percent of eligible psoriasis patients get the biologics they need” said Mark Levick, MD PhD, Global Head of Development, Biopharmaceuticals, Sandoz. “We are pleased the data reinforce the potential of our biosimilar adalimumab, if approved, to be another treatment option for moderate-to-severe chronic plaque psoriasis and other inflammatory diseases” Levick continued.

Results at week 17 demonstrated similar safety and immunogenicity between GP2017 and the reference medicine. Reported adverse events and the presence of anti-drug antibodies were similar across both treatment groups. Observed adverse events were in line with the reference medicine’s known safety profile.

Sandoz currently markets three biosimilars worldwide and the company plans to file biosimilar adalimumab with the EMA and the FDA in 2017. Sandoz also plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!